{
  "ticker": "LLY",
  "target_date": "2025-11-13",
  "actual_date": "2025-11-13",
  "collected_at": "2025-12-08T12:31:54.671771",
  "price": {
    "open": 1008.61,
    "high": 1031.44,
    "low": 1008.61,
    "close": 1021.3699951171875,
    "volume": 4153600,
    "change_1d_pct": 0.5,
    "change_7d_pct": 12.79,
    "change_30d_pct": 24.76
  },
  "technicals": {
    "rsi_14": 89.59,
    "sma_20": 879.94,
    "sma_50": 819.87,
    "macd": 52.883,
    "macd_signal": 37.951,
    "macd_histogram": 14.933,
    "bb_upper": 1030.47,
    "bb_lower": 729.41,
    "price_vs_sma20_pct": 16.07,
    "price_vs_sma50_pct": 24.58,
    "volume_ratio": 0.99
  },
  "fundamentals": {
    "market_cap": 892162736128,
    "pe_ratio": 48.760902,
    "forward_pe": 43.919243,
    "price_to_book": 37.470257,
    "price_to_sales": 15.01457,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.5,
    "pct_from_52w_low": 59.55
  },
  "macro": {
    "spy": {
      "price": 672.04,
      "change_1d_pct": -1.66,
      "change_7d_pct": -0.82
    },
    "vix": {
      "level": 20.0,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.11
    },
    "dollar_index": {
      "level": 99.18
    },
    "gold": {
      "price": 4186.9
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight",
      "source": "Yahoo",
      "datetime": 1763073060,
      "summary": "The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others,",
      "url": "https://finnhub.io/api/news?id=1a79aefb2b82934493f34c7df978affd65f5a85cc8593c483d454789834423d2"
    },
    {
      "headline": "Can Equities Stabilize after the Government Reopens?",
      "source": "Yahoo",
      "datetime": 1763056020,
      "summary": "As traders position for year-end, the government shutdown is over, major market indices are filling gaps, and seasonal momentum looms.",
      "url": "https://finnhub.io/api/news?id=1f74dbfaea93932409cf1179b01392a59cd4924be791d02d6c4687c69d5ab397"
    },
    {
      "headline": "Jim Cramer Discusses Key Point For Eli Lilly (LLY)\u2019s Drugs",
      "source": "Yahoo",
      "datetime": 1763051821,
      "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) is the pharmaceutical giant best known for its weight loss drugs. Cramer regularly ",
      "url": "https://finnhub.io/api/news?id=77c271fa7352ead17a154c0921408159a3c82ef9caa52f04e73e8421f40752d5"
    },
    {
      "headline": "Jim Cramer Praises Johnson & Johnson (JNJ)\u2019s Drugs",
      "source": "Yahoo",
      "datetime": 1763051771,
      "summary": "We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recent",
      "url": "https://finnhub.io/api/news?id=fc4c22310a57aad4fceefa790e332f5c66a104d62907919d0b0366cbd772c3c9"
    },
    {
      "headline": "Hypoglycemia Market Report 2025: Pipeline Holds 16 Molecules, with No Assets in the Pre-registration Stage, Three Assets in Phase III Development, and Another Four in Phase II",
      "source": "Yahoo",
      "datetime": 1763049240,
      "summary": "Key market opportunities in hypoglycemia therapeutics include leveraging the high incidence in India for market expansion and innovation, targeting the three Phase III pipeline assets for accelerated development, and capitalizing on recent strategic alliances and M&A activities to enhance competitiv",
      "url": "https://finnhub.io/api/news?id=9910ec4c2c9c09b136405d46cfe1e0615e080f84651b1b209878d6ee7059fd86"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-11-13",
      "description": "xslF345X05/wk-form4_1763068481.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000156153925000006/xslF345X05/wk-form4_1763068481.xml"
    },
    {
      "form": "4",
      "date": "2025-11-13",
      "description": "xslF345X05/form4-11132025_041101.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000069/xslF345X05/form4-11132025_041101.xml"
    },
    {
      "form": "4",
      "date": "2025-11-12",
      "description": "xslF345X05/form4-11122025_041107.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000065/xslF345X05/form4-11122025_041107.xml"
    },
    {
      "form": "4",
      "date": "2025-11-12",
      "description": "xslF345X05/form4-11122025_041105.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000031601125000064/xslF345X05/form4-11122025_041105.xml"
    },
    {
      "form": "4",
      "date": "2025-11-10",
      "description": "xslF345X05/wk-form4_1762815690.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000153860425000006/xslF345X05/wk-form4_1762815690.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}